Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)
- Response deadline
- Jan 7, 2028 Due in 509 days
- Date posted
- Nov 6, 2024
- Source
- Open notice
Description
The purpose of this Notice of Funding Opportunity (NOFO) is to invite research grant applications (R01) for the development and use of current and emerging molecular imaging methods to gain fundamental insights into cancer inflammation in vivo. The motivation for this initiative is that much of current imaging research into the role of inflammation in cancer is largely based on in vitro and ex vivo methods with limited utilization of imaging approaches that could lead to significant new insights relevant to dynamic cancer and inflammation interactions. Utilization of molecular imaging probes in pre-clinical and clinical investigations for precise temporal resolution at the molecular and cellular level are valuable approaches for identification and characterization of in vivo inflammatory cellular physiology in cancers and of molecular changes in response to treatment. This FOA encourages applications that focus on developing integrated imaging approaches to interrogate the role of inflammation in cancer through strong cross-field collaboration between cancer basic science researchers and imaging scientists. These collaborations are expected to advance science and understanding of cancer inflammation interactions.
Classifications
- NAICS93.394
Documents (1)
- DownloadPAR-24-311-Full-Announcement.htmltext/html422 B
Contacts
- grantsinfo@nih.gov301-402-2541
Similar contracts
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)Due Nov 10, 2026
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)Due Nov 10, 2026
- Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)Due Jan 7, 2028
- Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)Due Jan 7, 2028
- Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)Due Jan 7, 2028
- Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)Due Oct 14, 2026